| 170.69 2.81 (1.67%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 206.24 | 1-year : | 240.89 |
| Resists | First : | 176.58 | Second : | 206.24 |
| Pivot price | 163.04 |
|||
| Supports | First : | 154.5 | Second : | 140.86 |
| MAs | MA(5) : | 164.74 |
MA(20) : | 159.66 |
| MA(100) : | 127.2 |
MA(250) : | 104.18 |
|
| MACD | MACD : | 4.1 |
Signal : | 3.8 |
| %K %D | K(14,3) : | 70.2 |
D(3) : | 61.2 |
| RSI | RSI(14): 62.5 |
|||
| 52-week | High : | 176.58 | Low : | 53.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GH ] has closed below upper band by 3.4%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 170.96 - 171.62 | 171.62 - 172.28 |
| Low: | 163.29 - 164.08 | 164.08 - 164.86 |
| Close: | 169.4 - 170.63 | 170.63 - 171.85 |
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Fri, 21 Aug 2026
Guardant Health (NASDAQ: GH) insider plans more sales after June disposals - Stock Titan
Fri, 21 Aug 2026
Ninepoint Partners LP Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Thu, 20 Aug 2026
MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH - MarketBeat
Thu, 20 Aug 2026
Eagle Health Investments LP Acquires New Position in Guardant Health, Inc. $GH - MarketBeat
Wed, 19 Aug 2026
How Investors Are Reacting To Guardant Health (GH) Expanding Blood-Based Cancer Screening Acceptance - simplywall.st
Wed, 19 Aug 2026
7,149 Shares in Guardant Health, Inc. $GH Purchased by Perigon Wealth Management LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 134 (M) |
| Shares Float | 129 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 98.1 (%) |
| Shares Short | 11,420 (K) |
| Shares Short P.Month | 13,090 (K) |
| EPS | -3.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.38 |
| Profit Margin | -38.4 % |
| Operating Margin | -38.3 % |
| Return on Assets (ttm) | -18.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 44.2 % |
| Gross Profit (p.s.) | 5.73 |
| Sales Per Share | 8.79 |
| EBITDA (p.s.) | -3.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -185 (M) |
| Levered Free Cash Flow | 27 (M) |
| PE Ratio | -48.63 |
| PEG Ratio | 0 |
| Price to Book value | -123.69 |
| Price to Sales | 19.41 |
| Price to Cash Flow | -123.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|